Span Divergent
25.42
-1.33(-4.97%)
Market Cap₹18.44 Cr
PE Ratio-5.35
IndustryHealthcare
Company Performance:
1D-4.97%
1M-19.17%
6M0.00%
1Y0.00%
5Y+89.00%
View Company Insightsright
More news about Span Divergent
02Jan 26
Span Divergent Ltd Dispatches Postal Ballot Notice for Independent Director Approval
Span Divergent Limited has officially dispatched its postal ballot notice to shareholders seeking approval for regularizing Mr. Dharmesh Vinodbhai Desai as Non-Executive Independent Director. The e-voting process through NSDL runs from January 06 to February 04, 2026, with Mr. Mitesh Rana appointed as Scrutinizer to ensure fair and transparent voting.
 no imag found
10Nov 25
Span Divergent Sells Stake in Inactive Subsidiary, Explores Fund-Raising Options
Span Divergent Limited has announced several corporate actions following its board meeting on November 10, 2025. The company will divest its 99% stake in Span Diagnostics LLP to promoters for INR 99,000. The board approved exploring fund-raising options including FPO and Preferential Allotment. Management changes include appointing Mr. Dharmesh Vinodbhai Desai as an Additional Non-Executive Independent Director and resignations of two other directors. The company plans to revive operations of its subsidiary, Aranya Agri Biotech LLP. For Q2 FY2026, Span Divergent reported a consolidated total income of INR 786.26 lakhs, up 157.53% YoY, but recorded a net loss of INR 18.77 lakhs compared to a profit in Q2 FY2025.
 no imag found
13Aug 25
Span Divergent Reports Mixed Q1 Results: Standalone Profit Rises, Consolidated Loss Widens
Span Divergent Limited reported improved standalone results but faced challenges in consolidated financials for Q1. Standalone profit after tax increased by 80.50% to Rs 41.67 crore, while total income decreased by 11.72% to Rs 64.93 crore. Consolidated loss after tax widened to Rs 17.01 crore. The company operates in cashew processing, tissue culture, and trading segments. Several subsidiaries are facing financial difficulties, with Aranya Agri Biotech LLP set to discontinue operations. Management remains optimistic about turning around struggling subsidiaries. Span Divergent maintains a strong financial position with minimal outstanding loans.
 no imag found
Span Divergent
25.42
-1.33
(-4.97%)
1 Year Returns:0.00%
Industry Peers
Sun Pharmaceutical
1,865.00
(+1.47%)
Divis Laboratories
9,431.00
(-1.25%)
Torrent Pharmaceuticals
4,894.00
(+0.51%)
Zydus Life Science
1,200.50
(-1.19%)
Cipla
1,379.30
(-0.32%)
Laurus Labs
1,979.00
(-1.58%)
Mankind Pharma
2,545.00
(+4.49%)
Dr Reddys Laboratories
1,251.90
(+2.53%)
Aurobindo Pharma
1,697.70
(+0.01%)
Lupin
2,052.10
(-0.48%)